Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05013892 · ClinicalTrials.gov registry record · Phase 2
NTS-WBRT in Brain Metastases
A Phase 2 study of Brain Metastases, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT05013892 is a Phase 2 study of Brain Metastases that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 41 participants, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05013892, a Phase 2 study of Brain Metastases, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT). This research study involves: * NTS-WBRT (normal tissue sparing whole brain radiation therapy) * Memantine standard of care drug
Conditions Studied
Interventions
- DRUG Memantine
- RADIATION NTS-WBRT (normal tissue sparing whole brain radiation therapy)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-02-08 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05013892
The ClinicalTrials.gov registry entry for NCT05013892 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (81% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 2 interventions - of which Memantine is the first listed.
NCT05013892 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05013892 about?
NCT05013892 is a clinical study titled "NTS-WBRT in Brain Metastases". This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT). This research study involves: * NTS-WBRT (normal tissue sparing whole brain radiation therapy) * Memantine standard of care drug
What is the current status of trial NCT05013892?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2022-02-08. Estimated completion is 2027-12-31.
What conditions does trial NCT05013892 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT05013892?
The interventions under investigation include: Memantine (DRUG), NTS-WBRT (normal tissue sparing whole brain radiation therapy) (RADIATION).
Who is sponsoring clinical trial NCT05013892?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05013892 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
RECRUITING · Phase 2
-
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
RECRUITING · Phase 2
-
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
RECRUITING · Phase 2
-
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
RECRUITING · Phase 2
-
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.